Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Heart Test Laboratories Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
HSCS
Nasdaq
3845
https://heartsciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Heart Test Laboratories Inc
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- Mar 26th, 2024 1:00 pm
Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)
- Mar 16th, 2024 1:44 pm
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
- Mar 14th, 2024 8:15 pm
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
- Mar 12th, 2024 1:00 pm
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
- Mar 6th, 2024 2:00 pm
HeartSciences Adds Key Advisor to its Scientific Advisory Board
- Feb 26th, 2024 2:00 pm
HeartSciences Expands its Scientific Advisory Board
- Feb 12th, 2024 2:00 pm
HeartSciences Appoints New Scientific Advisory Board Member
- Feb 1st, 2024 2:00 pm
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
- Jan 18th, 2024 1:00 pm
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
- Jan 3rd, 2024 9:15 pm
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
- Dec 14th, 2023 9:15 pm
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
- Dec 5th, 2023 1:00 pm
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
- Nov 20th, 2023 1:00 pm
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
- Nov 13th, 2023 1:45 pm
HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments
- Oct 19th, 2023 1:00 pm
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
- Sep 26th, 2023 12:00 pm
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
- Sep 25th, 2023 12:00 pm
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
- Sep 21st, 2023 12:00 pm
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
- Sep 14th, 2023 8:15 pm
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
- Sep 12th, 2023 8:15 pm
Scroll